Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $699,050.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $12.71, for a total transaction of $699,050.00. Following the completion of the transaction, the chief executive officer now directly owns 221,017 shares of the company’s stock, valued at approximately $2,809,126.07. This represents a 19.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Monday, April 21st, Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.29, for a total transaction of $180,122.24.
• On Thursday, March 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.69, for a total value of $917,950.00.
• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total value of $876,150.00.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $12.62 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The firm has a market capitalization of $1.69 billion, a P/E ratio of -8.25 and a beta of 1.53. The business’s 50-day simple moving average is $13.13 and its 200-day simple moving average is $15.50.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.15. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Finally, Wall Street Zen raised shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after buying an additional 3,194 shares during the period. Osterweis Capital Management Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the first quarter worth about $47,000. Barclays PLC grew its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after buying an additional 4,952 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $147,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.